Meta-analysis of Virtual Reality Based on Delaying Mild Cognitive Impairment

J Nerv Ment Dis. 2022 Mar 1;210(3):194-198. doi: 10.1097/NMD.0000000000001426.

Abstract

To further clarify the effectiveness of virtual reality (VR) in improving cognitive function of patients with mild cognitive impairment (MCI) through meta-analysis, we searched the PubMed, Web of Science, Scopus, MEDLINE, and Cochrane centers for controlled trials of VR in patients with MCI. All analyses were performed using RevMan (Version 5.3; Cochrane Collaboration, Oxford, United Kingdom). The selected data were extracted as 2 × 2 table. All included studies were weighted and aggregated. According to the inclusion criteria and exclusion criteria, five articles were selected for meta-analysis. There was no bias or heterogeneity in the results. We found that the diamond is on the right side of the vertical line and does not intersect with the vertical line. We determined the following values: odds ratio, 1.34; 95% confidence interval, 0.31-2.37; z = 2.55; p = 0.01. VR can effectively improve the cognitive function of MCI patients and delay cognitive impairment, which can be further developed as a treatment to delay the development of MCI.

Publication types

  • Meta-Analysis

MeSH terms

  • Cognition
  • Cognitive Dysfunction* / therapy
  • Humans
  • United Kingdom
  • Virtual Reality*